Participants were randomized to 1 of 6 treatment sequences in which they received 1 of 3 treatments : evacetrapib 1200 mg daily for 10 days ( supratherapeutic dose ) , moxifloxacin 400 mg for 1 day ( positive control ) , or placebo for 10 days in each of the 3 separate treatment periods .